In addition, BEZ235, which is a dual inhibitor of PI3K and mammalian target of rapamycin (mTOR), was shown to be effective to suppress the stemness of CSCs in colon cancer by inhibiting PI3K/Akt/mTOR signaling[67]. This evidence concerns the gene MTOR and colonic neoplasm.